Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: 613 who wrote (57758)	7/5/2000 10:12:41 AM
From: steve h	Read Replies (1) \| Respond to of 122087

613, Below are the contraindications listed on the web site. Contraindications Cardiac catheterization within one to two weeks to minimize the likelihood of bleeding at the femoral puncture site. Arrhythmia that might interfere with the triggering of the EECP® treatment system such as atrial fibrillation, atrial flutter, ventricular tachycardia. Uncontrolled congestive heart failure. In some patients, left ventricular unloading may be insufficient to compensate for increased venous return during EECP® treatment. Aortic insufficiency where regurgitation would prevent diastolic augmentation. Limiting peripheral vascular disease (PVD) and/or phlebitis because of increased risk of thromboembolus. Severe PVD with reduced vascular volume and diminished musculature of the lower extremities can compromise effective counterpulsation. Severe hypertension (>180/110mmhg). Under these circumstances, EECP® treatment could produce diastolic blood pressure levels surpassing acceptable limits. Bleeding diathesis, Coumadin® (warfarin, Dupont Merck) therapy with PT>15 because the pressure of cuff inflations might cause bleeding in leg muscles. Pregnant women and women of childbearing potential who do not employ a reliable contraceptive method to avoid possible danger to fetus. NOTE: I am not a doctor nor any other type of medical expert. I also do not know the statistics of treatable angina via EECP. As I understand many angina patients also have different atrial and ventricular arrhythmias and/or are also on Coumadin. Again, I do not know what percentage of angina patients are free of these concern that could benefit from EECP. Even if a high percentage (50 to 60%??) of the reported 6.5 million people a year suffer from angina are not treateable due to these contraindication, there are still many patients that could benefit from EECP. I do see several positives: 1) non-invasive procedure - I personally would much rather try a non-invasive procedure before surgery. This is a huge plus. 2) VASO has patents - check the site 3) Limited competition 4) Company is profitable Just like any fairly new company that depends on the implementation of their technology to be successful, there are the obvious risks. nothing new there. And, I'll say it again. I am not an expert in this field and am a real newbie when it comes to analyzing companies. My apologies, if this is more than you wanted. Steve h